ArticleAnnals of neurosciences2026
Newfangled Combination Azilsartan and Ceftriaxone Exhibited Potential Effects in
Article in Annals of neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Excitotoxicity is an early event of cerebral ischemia, which is mainly caused by neuroinflammation, oxidative stress, and dysfunction of Excitatory Amino Acid Transporter-2 (EAAT-2). Generally, tissue plasminogen activators (tPA's) and anticoagulant therapies are being used as first-line treatment options for cerebral ischemia, but they only restore the cerebral blood flow (CBF) and fail to attenuate the detrimental events associated with ischemic insult in neurons, resulting in neurodegeneration. Based on the earlier studies, we designed a novel combination for targeting neuroinflammatory and excitotoxicity cascades in cerebral ischemia. Methods: Angiotensin receptor blocker (ARB) Azilsartan (Azi) and a third-generation cephalosporin Ceftriaxone (Cef) were evaluated in in vitro oxygen glucose-deprived (OGD) primary astrocytes and N2a neuronal co-cultures model of cerebral ischemia. Further, the above combination was also investigated in the middle cerebral artery occlusion (MCAo) rat model of cerebral ischemia. Then, neuro-biochemical estimations and molecular techniques like flow cytometry, ELISA and gene expression studies were performed to elucidate the possible mechanism. Results: The novel combination ameliorated the neurodegeneration by downregulating the ROS, apoptosis, oxidative stress, and excitotoxicity cascades and also enhanced the level of antioxidant enzymes. Moreover, EAAT-2 gene expression was remarkably increased with the treatment with a novel combination of Azi and Cef than with the individual treatment. The above combination significantly reversed the behavioural dysfunction in ischemic rats, which evidences the beneficial effects. Conclusion: The repurposing of anti-hypertensive, Azi, and antibiotic Cef combination demonstrated an excellent neuroprotective potential, mediating through ameliorating neuroinflammation, excitotoxicity and oxidative stress in in vitro OGD-induced astrocyte-neuron co-culture as well as cerebral ischemic rat model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.